Citigroup
PAND

Citigroup’s Pandion Therapeutics Inc. Common Stock PAND Stock Holding History

Citigroup’s Portfolio PAND Stock Details PAND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,396
Closed -$84K – 6620
2021
Q1 		$84K Sell
1,396
-911
-39% -$33K ﹤0.01% 4450
2020
Q4 		$34K Buy
2,307
+1,948
+543% +$27.1K ﹤0.01% 6315
2020
Q3 		$4K Buy
+359
New +$6.14K ﹤0.01% 7181

Citigroup's PAND Position: Q2 2021 in Review

Citigroup sold out of Pandion Therapeutics Inc. Common Stock (PAND) in Q2 2021, closing a stake of 1,396 shares — an estimated $84K sold.

Citigroup first reported a position in PAND in Q3 2020 and held it in 3 quarters. The position peaked at $84K in Q1 2021. 0 funds tracked by Wall St. Rank hold PAND as of Q2 2021.

  • Citigroup reported no remaining Pandion Therapeutics Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Citigroup sold 1,396 Pandion Therapeutics Inc. Common Stock shares in Q2 2021, an estimated $84K.
  • Citigroup first reported a position in Pandion Therapeutics Inc. Common Stock in Q3 2020 and held it in 3 quarters.
  • Citigroup's Pandion Therapeutics Inc. Common Stock position peaked at $84K in Q1 2021.
  • 0 funds tracked by Wall St. Rank held Pandion Therapeutics Inc. Common Stock as of Q2 2021.

Based on Citigroup's 13F filing for Q2 2021, filed 10 Aug 2021.